Septerna, Inc.

NASDAQ:SEPN

Biotechnology

Healthcare
$39.45 -2.04%

-$0.73 today

Market cap
$1.88B
Beta
2.38
P/E (TTM)
-43.6
EPS (TTM)
-$0.81
52W Low $9.96High $37.32

Volume 0.30M

Average 0.32M

SEPN EBITDA Margin

EBITDA as a percentage of revenue.

Septerna, Inc.NASDAQ: SEPN

EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026

EBITDA Margin narrows to -144.2%

EBITDA Margin was -144.2% in Q3 FY2026, down 100.1 pp from a year earlier. On a trailing-twelve-month basis it was -59.3%, up 282.9 pp year over year.

Context

  • EBITDA Margin widened in 2 of the last 2 fiscal years.
  • FY2025 was the highest level in the 3 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 7 analysts of -37.8% for the fiscal year ending Dec 2026, up from -102.9% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-144.2%-100.7 pp QoQ
Last fiscal yearDec 2025
-102.9%+6492.0 pp YoY
LTMSep 2026
-59.3%+282.9 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-100.1 pp-7.2 pp+92.9 pp
1 year+6492.0 pp+65.1 pp-6427.0 pp
3 years—-35.9 pp—
5 years-45.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-102.9%
Year-over-year change
+6492.0pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How SEPN compares with its peers on the latest reported figures

  • SEPN's LTM Sep 2026 EBITDA Margin of -59.3% is the 2nd highest of the 3 companies compared; the peer median is -299.8%.
  • Its year-over-year change of +282.9 pp is the 2nd highest of 3, against a peer median of +66821.7 pp.
SEPN Competitors Peer median
EBITDA Margin for SEPN and competitors
Company Period LTM level YoY 3-year change
VTVTvTv Therapeutics Inc.LTM Mar 2026-1.9% +134274.5 pp—
SEPNSepterna, Inc.LTM Sep 2026-59.3% +282.9 pp—
MAZEMaze Therapeutics, Inc.LTM Mar 2026-597.6% -631.1 pp—
MBXMBX Biosciences, Inc. Common StockFY2025— ——
KLRAKailera Therapeutics, Inc.FY2025— ——
GPCRStructure Therapeutics Inc.FY2025— ——
BMEABiomea Fusion, Inc.FY2025— ——
Peer median (excluding SEPN) -299.8%+66821.7 pp—

Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue151K1.08M45.95M
Cost of Revenue000
Gross Profit151K1.08M45.95M
Gross Margin100.0%100.0%100.0%
Research & Development35.98M65.34M97.58M
Selling, General & Admin9.72M16.56M29.16M
Operating Expenses(1.92M)81.9M126.75M
Depreciation & Amortization848K1.4M1.6M
EBITDA(44.7M)(70.9M)(47.26M)
EBITDA Margin-29604.0%-6594.9%-102.9%
Operating Income2.08M(80.82M)(80.8M)
Operating Margin1374.2%-7518.4%-175.8%
Interest Income2.79M8.62M19.53M
Interest Expense000
Other Income / Expenses2.8M8.53M31.93M
Income Before Tax4.87M(72.3M)(48.87M)
Pre-Tax Margin3225.8%-6725.2%-106.3%
Income Tax Expense691K(498K)12K
Net Income4.18M(71.8M)(48.88M)
Net Margin2768.2%-6678.9%-106.4%
EPS (Basic)0.03(1.93)(1.10)
EPS (Diluted)0.03(1.93)(1.10)
Weighted Avg Shares19.5M37.19M44.26M
Weighted Avg Shares (Diluted)19.5M37.19M44.26M

Septerna, Inc.

NASDAQ:SEPN

Intrinsic Alpha fair value

Locked

Current Price

$39.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.